A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

Weinstein, Jules B; Bates, Timothy A.; Leier, Hans C.; McBride, Savannah K.; Barklis, Eric; Tafesse, Fikadu G.

doi:10.1016/j.isci.2022.103960

Cited by 25 publications

(17 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, RBD capture capability of VHH EE -Cts1 in this study could be shown at concentrations in the low nanomolar range of 2.6 nM (0.1 ng/µl) in plate based ELISA, which is in the described range of other anti-RBD nanobodies between 0.9 nM and 30 nM ( Weinstein et al 2022 ), ( Huo et al 2020 ), ( König et al 2021 ). Moreover, published detection capacity of commercially available antigen tests is in the range of 0.65 pg/µl (nucleocapsid protein) to 5 ng/µl (spike protein) ( Baker et al 2020 ) ( Grant et al 2020 ).…”

Section: Discussionmentioning

confidence: 58%

Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis

Philipp

Müller

Andrée

et al. 2023

Journal of Biotechnology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 58%

Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis

Philipp

Müller

Andrée

et al. 2023

Journal of Biotechnology

View full text Add to dashboard Cite

“…Importantly, RBD capture capability of VHH EE -Cts1 in this study could be shown at concentrations in the low nanomolar range of 2.6 nm (0.1 ng/μl) in plate based ELISA, which is in the described range of other anti-RBD nanobodies between 0.9 nm and 30 nM (Weinstein et al 2022), (Huo et al 2020), (König et al 2021). Moreover, published detection capacity of commercially available antigen tests is in the range of 0.65 pg/μl (nucleocapsid protein) to 5 ng/μl (spike protein) (Baker et al 2020) (Grant et al 2020).…”

Section: Discussionmentioning

confidence: 58%

Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized inUstilago maydis

Philipp

Müller

Andrée

et al. 2022

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic has greatly impacted the global economy and health care systems, illustrating the urgent need for timely and inexpensive responses to a pandemic threat in the form of vaccines and antigen tests. The causative agent of COVID-19 is SARS-CoV-2. The spike protein on the virus surface interacts with the human angiotensin-converting enzyme (ACE2) via the so-called receptor binding domain (RBD), facilitating virus entry. The RBD thus represents a prime target for vaccines, therapeutic antibodies, and antigen test systems. Currently, antigen testing is mostly conducted by qualitative flow chromatography or via quantitative ELISA-type assays. The latter mostly utilize materials like protein-adhesive polymers and gold or latex particles. Here we present an alternative ELISA approach using inexpensive materials and permitting quick detection based on components produced in the microbial modelUstilago maydis. In this fungus, heterologous proteins like biopharmaceuticals can be exported by fusion to unconventionally secreted chitinase Cts1. As a unique feature, the carrier chitinase binds to chitin allowing its additional use as a purification or immobilization tag. In this study, we produced different mono- and bivalent SARS-CoV-2 nanobodies directed against the viral RBD as Cts1 fusions and screened their RBD binding affinityin vitroandin vivo. Functional nanobody-Cts1 fusions were immobilized on chitin forming an RBD tethering surface. This provides a solid base for future development of an inexpensive antigen test utilizing unconventionally secreted nanobodies as RBD trap and a matching ubiquitous and biogenic surface for immobilization.

show abstract

“… 35 In recent years, nanobodies have emerged as a promising tool for diagnosing and treating various diseases. 36 , 37 , 38 , 39 , 40 , 41 In August 2018, the first nanobody drug, Caplicizumab, was approved for the treatment of a blood clotting disorder. 42 …”

Section: Introductionmentioning

confidence: 99%

Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins

Ding

Zhu

et al. 2023

iScience

View full text Add to dashboard Cite

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

Cited by 25 publications

References 81 publications

Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis

Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis

Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized inUstilago maydis

Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins

Contact Info

Product

Resources

About